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Gut microbiota influences many aspects of host health including immune, metabolic, and
gut health. We examined the effect of a fermented whey concentrate (FWC) drink rich
in L-(+)-Lactic acid, consumed daily, in 18 healthy men (n = 5) and women (n = 13) in
free-living conditions.
Objective: The aims of this 6-weeks pilot trial were to (i) identify changes in the gut
microbiota composition and fecal short chain fatty acid (SCFA) profile, and (ii) to monitor
changes in glucose homeostasis.
Results: Total fecal SCFA (mM) concentration remained constant throughout the
intervention. Proportionally, there was a significant change in the composition of
different SCFAs compared to baseline. Acetate levels were significantly reduced (−6.5%;
p< 0.01), coupled to a significant increase in the relative amounts of propionate (+2.2%;
p < 0.01) and butyrate (+4.2%; p < 0.01), respectively. No changes in the relative
abundance of any specific bacteria were detected. No significant changes were observed
in glucose homeostasis in response to an oral glucose tolerance test.
Conclusion: Daily consumption of a fermented whey product led to significant changes
in fecal SCFA metabolite profile, indicating some potential prebiotic activity. These
changes did not result in any detectable differences in microbiota composition. Post-hoc
analysis indicated that baselinemicrobiota compositionmight be indicative of participants
likely to see changes in SCFA levels. However, due to the lack of a control group
these findings would need to be verified in a rigorously controlled trial. Future work is
also required to identify the biological mechanisms underlying the observed changes
in microbiota activity and to explore if these processes can be harnessed to favorably
impact host health.
Clinical Trial Registration: www.clinicaltrials.gov, identifier NCT03615339;
retrospectively registered on 03/08/2018.
Keywords: fermented whey concentrate, microbiota, short chain fatty acids, dietary supplementation, postbiotic
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INTRODUCTION
Over the past decades, an increasing amount of evidence has been
emerging on the importance of the gut microbiota driving many
biological functions that are directly associated with host health
(1). This has subsequently led to an interest in understanding
mechanisms and to potentially modulating the microbiota for
health benefits.
Within a healthy individual, the intestinal microbiota is
reasonably stable in composition, but there is potential for
targeted modification toward a more favorable community
composition to optimize health benefits. Human intervention
studies have shown a clear link between dietary intake and the gut
microbiota, where the species composition will adapt in response
to dietary change, determined by competition for substrates and
gut conditions (2, 3). Therefore, dietary intake is considered the
primary modulator of long-term microbiota composition. This
association has been observed in long-term prospective studies.
These longitudinal data contribute to the increasing causal
evidence for the role of the gut microbiota and its metabolites
(including short-chain fatty acids, SCFA) on various clinically
important indicators of health, such as immune cell function and
gut barrier integrity (4–7). In addition, evidence from human
intervention studies targeting modification of the microbiota has
shown encouraging effects on systemic inflammation, metabolic
health, allergies, and a variety of gastrointestinal diseases (8–
15). The most salient evidence for the direct link between the
gut microbiota and host health comes from the overwhelming
success of invasive fecal microbiota transplants (FMT) in the
treatment of recurrent Clostridium difficile infection (16). This
approach focuses on correcting the underlying gut microbiota
dysbiosis via drastic changes in the microbiota by replacing host
microbiota with those of a healthy donor.
For less invasive approaches, specific foods and dietary
patterns can also favorably influence the gut microbiota and
metabolite production. In specific instances these health effects
have been attributed to prebiotics. A prebiotic is defined
as a “selectively fermented ingredient that results in specific
changes in the composition and/or activity of the gastrointestinal
microbiota, thus conferring benefit(s) upon host health” (17,
18). Prebiotic supplementation can affect the composition
and the activity of the gut microbiota (19, 20). Much of
the research on these compounds has focused on dietary
fibers (particularly oligosaccharides) but other non-carbohydrate
compounds, mainly derived from plant materials as well
as polyphenols, have been investigated as naturally-occurring
prebiotics (21, 22). An example are cocoa-derived flavanols since
they are reported to stimulate lactic acid bacteria in vivo and
in vitro in healthy volunteers (n = 22) consuming them daily
for 4 weeks (23). Further research has shown that lactic acid
bacteria in the human gut can convert phenolic compounds,
such as flavonoids to biologically active metabolites, and it is
believed that these metabolites confer the health benefits to host
health. Consumption of a fermented milk product over a 4-weeks
period, increased the production of bacterial metabolites, such as
butyrate and other short chain fatty acids (SCFAs) in participants
with irritable bowel syndrome (IBS-Constipation type Rome III
criteria). Patients (n = 28) also experienced improvements in
self-reported symptoms (i.e., abdominal distention, acceleration
of colonic transit time), further strengthening the role of this
fermented milk in improving gut health (24). The study authors
suggest that these findings were compatible with the observation
that butyrate (a short chain fatty acid) has previously been shown
to also improve intestinal motility and visceral sensitivity in IBS-
C (17, 18, 25, 26). Consequently, renewed efforts are investigating
fermentation-derived metabolites in foods, assessing their ability
to favorably modulate microbiota composition and activity,
thereby acting as potential prebiotics.
Fermented foods are produced through controlled microbial
growth, and these food and drink products have recently surged
in popularity due to their proposed health benefits (27). Yet,
there is limited evidence on the real-world effectiveness of
most commercially available fermented food and beverages
on gastrointestinal health. Several studies have shown
that microorganisms from fermented foods can reach the
gastrointestinal tract, in the same way as probiotics which
are considered “live microorganisms that, when administered
in adequate amounts, confer a health benefit on the host”
(28). Studies however indicate that the presence of probiotic
species of bacteria appears to be transient when consumption is
discontinued in animal and human studies (29, 30).
At present, there is insufficient clinical evidence to make
evidence-based recommendations for the consumption of
fermented foods to improve the gut microbiota profile. A
recent critical review by Stiemsma et al. identified 19 human
interventions using fermented foods without probiotic bacterial
addition post-fermentation. The heterogeneity in the findings,
largely attributed to the variety of foods investigated, highlighted
the need to study the bioactive compounds and other beneficial
by-products of fermentation individually to ascertain their
relative role in mediating health effects (31).
In this study we evaluate a deproteinised whey concentrate,
high in L-(+)-Lactic acid, fermented by a member of the genus
Lactobacillus, establishing its potential as a putative prebiotic.
The main aim was to investigate the effect of daily consumption
of the whey product on fecal short chain fatty acid composition,
on gut microbiota metabolism and composition, and determine
if these could be linked to improvement in glycemic control. We
also explored the potential underlying physiological mechanisms
via assessment of self-reported intestinal function (regularity and
consistency of bowel movements).
MATERIALS AND METHODS
Study Design
The study was a 6-weeks single-arm intervention study, whereby
participants acted as their own control. Participants were 18
healthy adults who attended study visits at the Human Nutrition
Unit at the Rowett Institute (University of Aberdeen, UK,
Figure 1). Volunteer eligibility was assessed with a health
questionnaire during the screening process. The inclusion criteria
limited age to 18–65 years and BMI to 18–40 kg/m2. Any chronic,
uncontrolled disease or use of antibiotics within the last 3 months
were deemed exclusion criteria. Enrolled participants were
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FIGURE 1 | Flow diagram of study participants. *1 participant excluded, as blood samples could not collected due to fainting. **6 participants data excluded as
values below threshold of detection of kit. Adapted from (32).
instructed to cease consumption of any probiotics/prebiotics or
other food supplements 2-weeks prior to study commencement
(washout period) and during the entire intervention. At baseline
(t1) and completion (t6), blood pressure, heart rate, and weight
measurements were taken (Figure 2).
Blood pressure monitored with the use of an automated
system (Omron M5-1; Omron Healthcare Inc., Bannockburn,
IL), the average of 3 measures taken was recorded in the
supine position.
Height of the participants was measured to the nearest 0.1 cm
using a stadiometer (Holtain Ltd, Crymych, Dyfed, Wales). The
body weight of the participants was measured wearing a pre-
weighed dressing gown, to the nearest 100 g on a digital scale
(DIGI DS-410, C.M.S. Weighing Equipment Ltd, London, UK).
Ethics Statement
The study was conducted according to the guidelines in the
Declaration of Helsinki and Good Clinical Practice. The study
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FIGURE 2 | Study Flow (6 weeks continuous intake), single arm intervention, with three separate study visits at the Human Nutrition Unit (referred to as t1, t3, and t6).
FD, 3-days food diary; GI-Q, gastrointestinal questionnaire; OGTT, oral glucose tolerance test.
protocol was approved by the research ethics committee of the
Rowett Institute, University of Aberdeen (Reference No. 799). All
study participants provided written informed consent. The study
was retrospectively registered at ClinicalTrials.gov in August
2018 (NCT03615339).
Fermented Whey Concentrate Intervention
The investigated product, Molkosan R© (A.Vogel, Roggwil,
Switzerland) is made of deproteinised fermented organic whey
(FWC) concentrate rich in L-(+)-Lactic acid (70 g/L) (33).
This filter-sterilized concentrate is naturally lactose-free and
fermented by a member of the genus Lactobacillus. The
concentrate was provided to the participants in 1 L bottles
to take home, and they were asked to drink 20ml of the
supplement every morning and evening, diluted in ∼200ml
water. Participants were provided with 20ml measuring cups
to allow for accurate measuring of this step. Compliance of
daily consumption of the supplement was assessed by the return
of empty bottles. The daily supplement intake added 8 kcal
in energy intake (∼400 kcal for the whole study period, more
detailed nutritional information is shown in Table 1). Apart from
the high lactic acid content, the SCFA profile of the FWC was
quantified to reveal low levels of acetate in addition to the lactic
acid (see Supplementary Table 2).
Food Diary and Gastrointestinal
Questionnaire
Habitual food intake was recorded using a 4-days weighed
food diary prior to study commencement. Measurement of
food intake was repeated at week 3 of the intervention, just
prior to t3 (Figure 2). Participants recorded details of all foods
and drinks consumed or leftover (g) using calibrated kitchen
scales (Disc Electronic Kitchen Scale 1036, Salter Housewares,





Energy 90 kJ/20 kcal 36 KJ/8 kcal













Dietary fiber 0 g 0 g
Sodium 0.1 g <0.1 g
L-(+)-Lactic acid 7.0 g 2.8 g
UK), which were provided. Nutritional analyses were conducted
using the software NetWISP (version 3.0 for Windows, Tinuviel
Software, Anglesey, UK) a computerized version of McCance
and Widdowson: The Composition of Foods. Participants also
completed a brief gastrointestinal symptom questionnaire (GI-
Q) and were asked to record the number of bowel movements
over the same 4 days. The questionnaire asked participants to
record the severity of nausea, bloating, flatulence, cramps and
rumbles on a 3 point hedonic scale, ranging from “slightly more
symptoms than usual,” “noticeably more symptoms than usual”
to “considerably more symptoms than usual” (16).
Oral Glucose Tolerance Test (OGTT)
Volunteers were requested to fast from 10 p.m. the previous
evening prior to study visits on days 0 (t1), 21(t3), and 42
(t6). After baseline blood samples were taken participants were
given 113ml of Polycal (Nutricia Advanced Medical Nutrition,
UK), dissolved in 87mL of water, corresponding to 75 g of
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Change 0.14 0.03 0.21 0.09 0.15 −0.03 −0.15
% change 3.03 1.93 8.51 2.74 8.64 −5.51 −12.66
p-value ns ns 0.05 ns 0.04 ns ns
logv ns ns 0.04 ns ns ns ns
Mean ± SEM (Range) (n = 17).
aNon-esterified fatty acids.
The bold values are significant p-values.
anhydrous glucose to drink. An oral glucose tolerance test
(OGTT) was then carried out by collecting 5ml of venous blood
at 0, 15, 30, 45, 60, 90, 120, 150, and 180min post-glucose intake,
via a cannula into lithium heparin tubes (S-Monovette R©, Cat
#04.1936, Sarstedt, Germany). Plasma was analyzed for glucose
and insulin concentration [see section Oral Glucose Tolerance
Test (OGTT)]. The total area under the curve (tAUC) was
calculated using the trapezoid method for (a) the total duration
of the OGTT and (b) each incremental area under the curve
(iAUC). For anymissing data during OGTT, values were imputed
based on the mean of the value recorded on the preceding
and subsequent time point. Statistics were performed using
log-transformed data for a two-way ANOVA using Genstat 17
Release 17.1 (Lawes Agricultural Trust, VSN international Ltd,
Hemel Hempstead, UK).
Blood Sample Analysis
One participant was unable to provide blood samples, so the
data presented is for n = 17 (94.4%). Biochemical parameters,
including glucose, and the fasting lipid profile (total cholesterol,
LDL, HDL, non-esterified fatty acids and triglycerides),
were measured using a Konelab30 clinical autoanalyser
(Kone Limited, Thermo Fisher Limited, USA). Insulin was
quantified, in duplicate, by enzyme-linked immunosorbent assay
(Mercodia insulin, Mercodia Inc., Sweden) as per manufacturer’s
instructions. Complete data were available from 12 individuals
for both baseline (t1) and end-of-study (t6) insulin levels above
the detection threshold of the assay (>2 mIU/L).
Fecal Sample Processing and DNA
Extraction
Participants self-collected stool samples within 16 h preceding
their study visits (Fecontainer, AT Medical BV, The Netherlands)
and kept cold at 4◦C. Fresh feces (5 g) were diluted 1:2
(w/v) with phosphate-buffered saline (pH 7.4, 30% glycerol)
and homogenized by gentleMACS Dissociator (Miltenyi Biotec,
Bergisch Gladbach, Germany). Aliquots (450 µl) were used
for DNA extraction using FastDNATM SPIN kit for Soil (MP
Biomedicals, Santa Ana, USA) and stored at−70◦C.
Short Chain Fatty Acid Quantification
The SCFA content of the samples was determined by capillary
gas chromatography following conversion to t-butyldimethylsilyl
derivatives. SCFA were quantified in mM against authentic
standards of acetate, propionate, butyrate, valerate, and the
branched chain fatty acids iso-butyrate and iso-valerate. Samples
were analyzed using a Hewlett Packard gas chromatograph fitted
with a fused silica capillary column with helium as the carrier gas.
The lower limit for reliable detection of each product was taken
as 0.2mM. The method used has been described previously (34).
16S rRNA Gene Sequencing
The V1–V2 region of the 16S rRNA gene was amplified by
PCR using primers containing adaptors for downstream Illumina
MiSeq sequencing. Primers used were 27F and 338R. The pooled
PCR amplicons were precipitated and re-suspended in TE buffer
(10mMTris-HCl, 0.1mMEDTA). Quantification was performed
using the Qubit dsDNA HS Assay Kit and Qubit fluorometer
2.0 (Invitrogen, USA). Prior to sequencing samples underwent
purification using AmPure XP beads (Beckman Coulter, USA)
Amplicon samples were provided to the Center for Genome
Enabled Biology and Medicine (Aberdeen, UK) and sequenced
using the Illumina MiSeq v2 flowcell (Illumina, CA, USA)
producing 250 bp paired end reads.
Bioinformatic Analysis
Quality of the sequences was assessed using FastQC
(version 0.11.3) and sequence variant abundances were
determined using DADA2 (version 1.3.1) (35, 36).
Taxonomy was assigned against the GreenGenes 13.8 database
(37). The outcome sequence variant was converted to biom
format using biomformat (version 2.1.3) (38). Diversity analysis
was performed using the core_diversity_analyses.py script from
QIIME (version 1.9.0) (39) with subsampling of 6,730 sequences
per sample.
Core diversity analyses calculated five alpha diversity
measures, including the Shannon Index, and two beta diversity
measures, Bray Curtis and Binary Jaccard (40–43). Figures were
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generated in R using ggplot2 unless otherwise stated. PCoA plots
were visualized using EMPeror (44).
Statistical testing of stratification of samples by meta
data category was performed using the adonis statistical test
on the Bray Curtis diversity metrics, implemented by the
compare_categories script from using QIIME (version 1.9.0)
(39, 45).
Differential abundance test of sequence variants between
volunteers classified responders (n = 5, Volunteers 18, 4, 14, 20,
12) vs. non-responders (n = 5, Volunteers 7, 15, 11, 21, 6) based
on the largest increase in butyrate concentration and repeated
for propionate levels (see Supplementary Tables 1A, B). This
comparison was carried out using a beta-binomial regression
model for abundance data using the R package corncob (46).
Comparisons were made at the taxonomic ranks of phyla, family,
genus and species at all three time points throughout the study.
Sensitivity analyses were run to test the influence of sequence
variants present in <5% of samples.
RESULTS
Study Group Characteristics and
Participant Anthropometry
Of the 22 participants enrolled, 18 completed the study (two were
excluded due to antibiotic intake, two due to time constraints;
Figure 1). Group characteristics are summarized in Tables 3,
4. Overall, the study group was largely female (72%; n = 13)
and had an average age of 39 (SD = 2.6) years. On average
participants weighed 69.2 (SD = 13.4) kg, ranging from 49.6 to
95.1 kg at baseline (t1). Blood pressure and heart rate remained
in a healthy range throughout the whole study period. Baseline
TABLE 3 | Baseline (t1) anthropometric characteristics including all participants
who completed the study (n = 18).
















Data shown as mean ± SEM (Range).
clinical biochemistry measured from blood samples indicated
all volunteers were in good health prior to and during the
intervention (see Table 2). Although there was a statistically
significant increase in mean LDL cholesterol at t6 up to 2.62
mmol/l (see Table 2), this is attributed to a single volunteer
experiencing a sharp increase to 5.22 mmol/l. Excluding this
volunteer’s measurements indicated average changes were non-
significant, t6= 2.46 mmol/l (n= 16, p= 0.15).
Energy Balance and Diet
Participant BMI did not change over the 6-weeks intervention
period. The 4-days food diaries indicated that dietary energy
intake and macronutrient composition, on average, remained
stable during the intervention (Table 5).
Oral Glucose Tolerance Test
There were no significant changes after the 6-weeks fermented
whey intervention in glycemic response in volunteers (n = 17)
(Figure 3). Fasting blood glucose was comparable before and
after FWC consumption (t1 = 5.08 mmol/L, SD = 0.38, t6 =
TABLE 5 | Average energy intake and macronutrient composition of study
participants diets as reported by 4 days weighed food diaries (n = 18).
Energy intake Baseline Intervention p-Value




































ns, not significant (p-value >0.05).
Data shown as mean ± SEM (Range).
TABLE 4 | Weight and BMI, as measured at initial enrollment and at the completion of the intervention (n = 18).





































Mean change −1.7 −1.0 2.0 0.8 0.6 0.3
Data shown as mean ± SEM (Range).
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4.96, SD = 0.43). In addition, analysis of tAUC (t1 = 1,004, SD
= 149.5, t6= 1,032, SD= 175.9, p= 0.619, n= 17) and iAUC (t1
= 148, SD= 89.5, t6= 194, SD= 136, p= 0.324, n= 17) showed
these were not significantly influenced by FWC intake.
Analysis of insulin levels at baseline (t1) and at week 6
(t6), showed strong interindividual variation (Figure 3). Seven
of the 12 volunteers had lower levels at t6 and the remaining
five showed little change as indicated by the individual insulin
responses shown in Figure 4A. On average the participants show
no significant change in their fasting insulin levels over the
duration of the intervention (t1 = 5.11 mIU/L, SD = 2.08, t6 =
4.075 mIU/L, SD= 1.16–0.9 mIU/L; p= 0.089, Figure 4B).
Self-Reported Gastrointestinal Well-being
There was no significant change in the average number of
daily bowel movements (1.2–1.3, n = 18). Subjective feelings of
gut health were assessed from two sets of daily questionnaires
completed in parallel with the 4-days food diaries (Table 6).
To monitor overall changes, we compared the proportion of
responses recorded as normal at baseline with the data collected
on day 21 (t3). There was no change from normal in the
reported feelings of nausea, flatulence, cramps and rumbles. On
the other hand, the proportion of days that participants reported
more bloating than usual declined following fermented whey
concentrate (FWC) consumption from 22.5% instances to 9.9%.
Short-Chain Fatty Acid (SCFA) Analysis
SCFA and branched chain fatty acids (BCFA) were quantified
to assess the impact FWC (rich in lactate) supplementation
on bacterial metabolic activity. The total SCFA + BCFA
concentration was relatively constant at each time point (t1
= 88.8mM, SD = 31.8 and t6 = 85mM, SD = 39; n =
18). No significant changes were observed in the levels of the
BCFA iso-butyrate and iso-valerate, and the SCFAs valerate
FIGURE 3 | Oral Glucose tolerance test showing group plasma glucose profile in response to a 75 g bolus of glucose, at commencement of study (Baseline) and after
6-weeks of chronic fermented whey consumption (Fermented whey, n = 17).
FIGURE 4 | Fasting insulin profiles pre- (t1) and post-intervention, t6 (n = 12). (A) Insulin concentration shown by individual volunteers, at baseline (t1) and after the
intervention (t6). (B) Group average fasting insulin levels. There was a reduction of −0.9 mUI/L which failed to reach significance (p = 0.089).
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or the intermediate metabolite succinate (p > 0.05, data not
shown). Lactate was not detected in any fecal samples (data
not shown). There was a significant decrease in the relative
proportion of acetate and a concomitant increase in propionate
and butyrate observed at week 6 (t6) of the intervention when
compared to baseline measurements (Figure 5). Acetate levels
were significantly reduced from an average of 66.98%, SD =
5.69% at t1 to 60.5%, SD = 5.41% (p < 0.01) at t6. In parallel a
significant increase in the relative amounts of propionate by 2.2%
(t1 = 13.63%, SD = 2.91; t6 = 15.79%, SD = 3.59, p < 0.05) and
butyrate by 4.2% (t1 = 11.34%, SD = 3.94; t6 = 15.55%, SD =
5.72, p < 0.01), were observed (Figure 5).
16S rRNA Gene Sequencing and
Microbiota Composition
Raw 16S rRNA gene sequence data generated between 14,299 and
141,814 reads per fecal sample, with an average read count of
62791. Analysis of raw sequencing reads using DADA2 produced
a total of 6,377 sequence variants across all samples.
TABLE 6 | Gastrointestinal symptoms were self-reported for 4 days (n = 18) just prior to baseline and week 3 of the trial (t3)a.
Scale Baseline symptoms (week-1)
Nausea Bloating Flatulence Cramps Rumbles
0—normal 68 55 43 63 49
1—“Slightly more than usual” 1 14 24 7 16
2—“Noticeably more than usual” 2 2 3 1 5
3—“Considerably more than usual” 0 0 1 0 1
% Normal 95.8 77.5 60.6 88.7 69
Fermented whey (week 3, t3)
0—Normal 67 64 40 64 51
1—“Slightly more than usual” 4 6 28 4 16
2—“Noticeably more than usual” 0 1 3 3 4
3—“Considerably more than usual” 0 0 0 0 0
% Normal 94.4 90.1 56.3 90.1 71.8
The table summarizes number of responses recorded for each level over 4-days (with 0 indicating “normal” function till 3 considered as “considerably more symptoms than usual”). The
percentage normal, refers to the proportion of responses being 0 on the scale.
aAt both time points t1 and t3, one volunteer only reported 3-days, only reporting 71 observations out of 72.
FIGURE 5 | Short chain fatty acid composition of fecal samples (n = 18). Values are proportions of total SCFA concentration. Boxplots whiskers represent min/max
values. Acetate levels decreased significantly (by 6.48%, p < 0.01), while both propionate (p < 0.05) and butyrate (p < 0.001) levels increased. No lactate or
succinate were detected. (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001).
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We did not observe any change in overall bacterial α-diversity,
measured by Shannon index, over the duration of the study,
as illustrated when the samples are grouped together based on
time point (Figure 5), suggesting that FWC supplementation
does not impact on the number of bacterial taxa within the gut.
Looking at relative abundance of taxa, when the samples are
grouped by volunteer the underlying inter-individual variation is
apparent at both phylum and genus level (Figure 7). Clustering
of samples based on microbiota composition according to Bray-
Curtis dissimilarity indices, showed no separation based on
fermented whey consumption (Adonis p = 1; Figure 7), with
any division of samples driven by the individual’s microbial
composition (Adonis p = 0.001; Figure 8). In fact, this figure
clearly shows that the three samples from each individual cluster
strongly together, illustrating that the microbiota within an
individual is stable through the duration of the study.
The volunteer group was split into responders (n = 5) and
non-responders (n = 5) according to the highest and smallest
change in butyrate levels. There were no significant differences
between these two groups in terms of alpha and beta diversity.
Since the responder group was based on higher than average
detection of butyrate following FWC supplementation, the
relative abundance of the following known butyrate-producing
species was investigated: Anaerostipes species, Coprococcus
eutactus (Figure 9), Eubacterium hallii, Eubacterium rectale,
Faecalibacterium prausnitzii, andRoseburia species (47), however
no differences in abundance of any of these bacterial groups
was observed (data not shown). A separate analysis was carried
out based on propionate and separately butyrate responders
(largest change in proportion of SCFA), compared to non-
responders (volunteers with smallest change in levels). Results
are summarized in Supplementary Tables 1A,B). For example,
some significant differences were observed between other
bacterial groups. A family of bacteria classed as Veillonellaceae,
in the genus Dialister, were significantly higher in the
butyrate responder volunteer sub-set (FDR = 0.0047; false
discovery rate correction for multiple testing) at t3 and t6
(Supplementary Table 1B).
DISCUSSION
We present the results of a diet study investigating the effects
of dietary supplementation with a fermented whey product
containing bacterially derived L-(+)-Lactic acid on various
health parameters and microbial activity. Following daily FWC
supplementation in healthy adults, a higher proportion of
butyrate and propionate were detected in fecal samples, although
total SCFA levels remained unchanged (Figure 5). This may
be attributable to the high L-(+)-Lactic acid content (70 g/L)
of the FWC influencing the activity of lactate utilizers within
the host microbiota. However, we were unable to detect a
significant change in the composition of themicrobiota following
the addition of FWC to the diet. No significant changes were
detected in alpha diversity (Figure 6, Shannon-diversity index),
bacterial abundance at the phylum level (Figure 7), or in beta
diversity (Figure 8, Bray-Curtis dissimilarity) over the course
of the supplementation. This may in part be due to the
large inter-individual variability in bacterial species composition
which our study was not sufficiently powered to overcome.
Further investigations would be needed to determine whether
oral ingestion of lactate might stimulate cross-feeding of lactate
utilizing species in the colon resulting in production of butyrate
or propionate in healthy volunteers (48, 49).
Lactate is rarely present in healthy adult feces due to extensive
cross-feeding between different bacterial species whereby any
lactate produced provides a substrate for lactate-utilizers in the
microbiota (1, 43). In this study lactate was not detected in
feces, even after supplementation with FWC rich in L-(+)-Lactic
acid. This could indicate that the L-(+)-lactic acid was either
not able to reach the colon and was absorbed in the upper
GI tract, or was completely metabolized by microorganisms
(50). There is considerable uncertainty on the biodistribution of
orally (exogenous) ingested L-(+)-lactic acid in humans due to
the continual flux of naturally occurring lactate from metabolic
processes, even at rest (51). Compared to endogenously produced
lactic acid, the lactic acid consumed from the FWC will
have a substantially different biodistribution, as it is subjected
to the multitude of digestive processes all along the human
gastrointestinal tract. In particular, the initial stages of exogenous
lactate digestion (absorption and distribution) will differ to
endogenous lactate, which is directly released from the human
cell into circulation (52, 53). In healthy adults, plasma lactate is
primarily cleared by the liver and mitochondria-rich tissue, such
as skeletal muscle (54, 55).
Exploring the fate of exogenous lactate, produced by
bacterial fermentation, within the gastrointestinal tract would
improve our understanding of dietary lactic acid intake and
the downstream effects on host-microbiota composition, and
eventually bioactivity. Commonly consumed fermented foods are
naturally rich in L-(+)-Lactic, yogurt can reach up to 2%. This
warrants further investigation into the effect of regular ingestion
of these levels and whether these contribute to the beneficial
health effect associated with regular yogurt consumption (56).
The FWC used in our study contains 7% L-(+)-lactic acid
(or 70 g/L), meaning that the daily intake of the volunteers
corresponded to 2.8 g of L-(+)-lactic acid, comparable with
concentrations in a pot of yogurt. It is important to note that
this lactic acid was administered independent of any live bacteria
or food matrix (in contrast to fermented foods), which may
have affected its absorption. It would be interesting to investigate
whether regular ingestion of these levels of lactate contribute
to the beneficial health effect associated with regular yogurt
consumption (56).
A further aspect to consider is that systemic lactate can cross
the gut epithelial barrier and thus it is possible that not all FWC
lactate directly reached the colon (56). Even if dietary lactate
is absorbed into circulation in the upper GIT, at least some
of it may reach the colon via indirect mechanisms (systemic
circulation and transport back into the colon). A previous study
by Scheiman et al., linked the presence of Veillonella bacteria,
conversion of circulating lactate to propionate, and enhanced
athletic performance (57). The results from our study were in
line with these previous findings yet it remains unknown if
Frontiers in Nutrition | www.frontiersin.org 9 September 2020 | Volume 7 | Article 165
Smith et al. Fermented Whey and Gut Health
FIGURE 6 | Microbiota alpha diversity metrics, analyzed by calculating the Shannon index comparing samples based on time point (t1—red, t3—green, t6—blue).
Differences over time were not significant.
FIGURE 7 | Taxonomic profile of individual volunteers at phylum level, grouped by time-point, t1, t3, and t6.
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FIGURE 8 | Principle component analysis plots based on Bray-Curtis Dissimilarity Index, comparing each sample from individual volunteers (n = 18).
this mechanism of peripheral lactate transport into the GIT
can be observed independent of exercise. Our data shows that
consumption of FWC [containing L-(+)-lactic acid] increases
relative amounts of butyrate produced in feces, but only in
participants who had higher levels of Veillonellaceae (Dialister)
species (see Supplementary Table 1A).
Overall, there were no changes in bacterial diversity as a result
of FWC supplementation. Both the alpha diversity (the number
of different taxa) and the Shannon index (sample richness)
indicated similar bacterial abundance levels across the study
period. However, when the data were stratified into responders
and non-responders based on increased fecal butyrate detection,
the Veillonellaceae family were significantly higher in responders
(FDR = 0.0047) at both sampling timepoints. This may indicate
that those individuals with a higher resident population of
bacteria capable of converting lactate to butyrate/propionate,
have higher concentrations of these SCFA in feces following
lactate consumption. Consequently, the modified SCFA profile
indicates that the lactic acid might stimulate microbial metabolic
activity without detectable changes in microbial composition.
Metatranscriptomic analysis of themicrobiota would showwhich
genes were differentially expressed by bacterial species following
FWC supplementation and provide detailed insights into changes
in metabolic activity. Confirmed prebiotic compounds, such as
inulin (a natural soluble fiber) have an effect on microbiota
composition as demonstrated in many studies including a study
with 12 healthy volunteers investigating the effects of inulin
consumption for 21 days on the microbiota where increases in
the Bifidobacteria population were observed (58).
There were no changes in fasting insulin levels following
the FWC supplementation, but inter-individual differences in
response profiles existed. Insulin sensitivity could be more
accurately studied with participants at risk of developing diabetes
to study any long-term effects on glycaemic control. Previous
data indicate that this benefit might be more pronounced in
persons with a higher BMI. This was shown in a double-blind,
randomized, placebo-controlled crossover study, where a daily
dose of 20 g inulin-propionate ester was able to alter insulin
sensitivity significantly (59).
There were several limitations associated with our study.
There is increasing evidence that gut microbiota richness is
linked to stool consistency and water content, which were not
assessed in this study (60). This pilot trial was exploratory and
thus did not use a control group or a cross over design with
placebo treatment. As the study was conducted in a non-blinded
manner, we cannot exclude treatment effect at least partially
explaining the observed changes in the subjective GI well-being
questionnaire. It is important to also bear in mind that the
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FIGURE 9 | Relative abundance of Coprococcus eutactus in volunteers with the highest (Responder, n = 5) and lowest (Non-responders, n = 5) changes in fecal
butyrate concentration. Kruskal-Wallis test show non-significant changes in abundance across sample types in both responders (p = 0.38) and non-responders (p =
0.38).
participants were free-living and were able to consume food ad-
libitum, and diet is one of the key factors affecting microbiota
diversity. Although in this study we collect 3-days food diaries to
monitor changes in energy intake, it was not possible to assess
changes in food intake patterns and food types consumed but
macronutrient intake was fairly consistent at both the timepoints
when diaries were completed. Weighed food diaries, as a dietary
assessment method, have their limitations, and in our study
also do not directly correspond with the timing of stool sample
collection which is a further source of uncertainty (57).
We observed increased fecal propionate and butyrate
concentrations following FWC consumption. The health effects
of fecal butyrate can be attributed to the fact that colonocytes
utilize bacterially-produced butyrate as their primary energy
source, whereas most other cell types utilize glucose (61).
Changes in gut permeability may improve gut health and
confer long-term benefit to the host which we were unable to
investigate in our short-term study. Changes in the microbiota
can be attributed to a huge variety of factors including diet,
immune challenges, exercise, variations in GI transit time,
intestinal pH, host secretions, regulation of gene expression
of the host and/or the microbiota and other environmental
factors. Therefore, it is incredibly difficult to definitively attribute
any changes in metabolic activity of the microbiota to the
FWC supplementation. As highlighted by Stiemsma et al.,
compositional changes to the gut microbiota in addition to
changes to immune or metabolic factors remain the most studied
links between fermented food consumption and health outcomes
(31). An increased focus on functional analyses, such as SCFA
production, and the balance of SCFA production and absorption
in humans as a result of fermented food consumption might shed
light on their health benefits.
Probiotics and prebiotics are established dietary interventions
seeking to correct underlying microbiota dysbiosis and leading
ultimately to improved host health. However, a potentially
new subtype of gut-directed supplements aiming to correct
underlying microbiota dysbiosis in order to influence host health
are post-biotics. The term post-biotic refers to “soluble factors
(products or metabolic byproducts) secreted by live bacteria or
released after bacterial lysis” (62). The key difference is that
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while probiotics, by definition, need to contain viable bacterial
cells, post-biotics do not (28). Post-biotics must originate from
bacteria, differentiating them from prebiotics, which tend to be
fermentable carbohydrates. At present the few studies which have
investigated the effectiveness of post-biotics indicate positive
effects on host immune response both in animal and humans
(62, 63).
This project was undertaken to evaluate the effect of
bacterially derived FWC, with a high L-(+)-Lactic acid content,
on microbiota composition and activity and determine potential
effects on host health. Based on our data it is likely that the effects
of FWCmight be linked to the high lactic acid content specifically
stimulating species of the resident microbiota. Consequently,
we could consider FWC as a putative prebiotic based on the
changes in microbial activity, or as a putative post-biotic since
the lactic acid component is a product of the Lactobacillus
fermentation of the whey, and is safe for human consumption
at these concentrations. Confirmation of the FWC in either
category would require establishment of a definitive health
benefit. Future controlled human studies are required to establish
our exploratory data in a larger participant group, with additional
biological measures to establish the biodistribution of L-(+)-
Lactic acid post-ingestion, and establish a health benefit. Taken
together, this will help us understand if microbiota driven effects,
such as the observed changes in SCFA profile, are directly
beneficial to the host.
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